Swedish Orphan Biovitrum AB (publ) (SOBI) Plunges -0.17% on Oct 18

October 18, 2017 - By Richard Conner

Shares of Swedish Orphan Biovitrum AB (publ) (STO:SOBI) last traded at 116.4, representing a move of -0.17%, or -0.2 per share, on volume of 217,866 shares. After opening the trading day at 116.1, shares of Swedish Orphan Biovitrum AB (publ) traded in a close range. Swedish Orphan Biovitrum AB (publ) currently has a total float of 269.12M shares and on average sees 541,745 shares exchange hands each day. The stock now has a 52-week low of 89.5 and high of 143.8.

OMXS30: Attesting To Sweden’s Glory

Many European countries are acknowledged for their respective contributions to the global economy given their extensive dominance. One of these European prides includes Sweden, a truly influential nation especially among Nordic countries. The chances to get to its market are low, but Swedish Orphan Biovitrum AB (publ) made it.

Sweden boasts with countless growth opportunities for domestic and international investors alike, which is why it has a healthy trade and commerce landscape backed by a reasonable borrowing environment. Moreover, its compelling corporate governance also attracts more and more investors through time, and strengthens their confidence in the national economy. Swedish Orphan Biovitrum AB (publ) receives attention of new investors from across the world.

Nasdaq Stockholm

The Nasdaq Stockholm, which is a part of the Nasdaq Nordic, is the main stock exchange in Sweden that is based in Frihamnen, Stockholm. It had been established in 1863, adopting a floor trading system at the Stockholm Stock Exchange Building. On June 1, 1990, an electronic trading system had finally been introduced.

Presently, the Nasdaq Stockholm is owned by Nasdaq, Inc. along with other stock exchanges in Nordic countries including the Armenia Stock Exchange or Nasdaq OMX Armenia; Copenhagen Stock Exchange or Nasdaq Copenhagen; the Helsinki Stock Exchange or Nasdaq Helsinki; the Iceland Stock Exchange or Nasdaq Iceland; the Riga Stock Exchange or Nasdaq Baltic; and the Tallinn Stock Exchange or Nasdaq Baltic.

The regular trading on the Nasdaq Stockholm lasts for eight hours, beginning at 9:00 a.m. and ending at 5:00 p.m. Currently, it has a total market capitalization of roughly $1.30 trillion with more than 300 companies listed on the Nasdaq Stockholm. Inside this list is Swedish Orphan Biovitrum AB (publ).


The OMXS30 is the benchmark Swedish index that weighs the 30 biggest companies listed on the Nasdaq Stockholm based on market capitalization.

The components are reviewed twice a year in order to make sure that the OMXS30 provides a meaningful representation of the Swedish equity market. Regular index rebalancing is a typical activity among indices that do not weigh all companies listed on their respective stock exchanges. Companies are regularly dropped from and added to these indices depending on several factors such as industry representation, liquidity, among others.

The base value of the OMXS30 is 125 points and the base date is September 1986. Numerous sectors comprise the OMXS30; and the top 3 largest sectors include Consumer Services, Financials, and Industrials.

The OMXS30 had reached its all-time low of 98.96 points in November 1987; and its all-time high of 1,719.93 points in April 2015. The remarkable decline in 1987 had been mainly driven by Black Monday, a dark day in the history of global economy that had started in Hong Kong. From there, the OMXS30 had managed to grow gradually as the Swedish economy recouped, leading to its all-time high record. Companies like Swedish Orphan Biovitrum AB (publ) received the benefits of investors attention after that.

There is no reason to doubt the rampant growth of the European economy with the powerful stability of countries such as Sweden. Many investors are considering entering the European equity market because of this. It goes without saying that investing on Nasdaq Stockholm stocks is one of the best ways to penetrate a booming economy and bet on its further growth.

More notable recent Swedish Orphan Biovitrum AB (publ) (STO:SOBI) news were published by: Prnewswire.com which released: “Auxilium Pharmaceuticals, Inc. And Swedish Orphan Biovitrum AB (publ) Enter A …” on July 16, 2013, also Businesswire.com with their article: “Swedish Orphan Biovitrum AB: European Commission Grants SOBI003 Orphan …” published on October 19, 2016, Prnewswire.com published: “Swedish Orphan Biovitrum AB – Elocta® Approved in the Kingdom of Saudi Arabia …” on May 18, 2017. More interesting news about Swedish Orphan Biovitrum AB (publ) (STO:SOBI) were released by: Businesswire.com and their article: “Swedish Orphan Biovitrum AB: Elocta® obtains reimbursement in UK, Italy and …” published on September 21, 2016 as well as Businesswire.com‘s news article titled: “Swedish Orphan Biovitrum AB: Health Canada Validates Orfadin® Capsule Filing” with publication date: July 14, 2016.

Swedish Orphan Biovitrum publ AB is a Sweden pharmaceutical company. The company has market cap of $31.72 billion. The Firm develops, makes and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. It has a 43.3 P/E ratio. The Company’s product portfolio is divided into three business divisions: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: